SUN PHARMA

Sun Pharma launches Favipiravir) in India

Sun Pharma launches Favipiravir) in India

Sun Pharmaceutical Industries Limited launched FluGuard (Favipiravir 200 mg) at a price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.  Kirti Ganorkar, CEO of India Business, Sun Pharma said, “With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard at an economical price to make the drug accessible to more and more patients…
Read More